Jazz Pharmaceuticals PLC (JAZZ) is a Healthcare · Biotechnology company listed on NASDAQ. Price $240.74 (-1.27%), Market cap $14.34B, P/E ratio 2077.91, 52-week low–high $97.78 ~ $228.57.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to
Financial statements, price targets, institutional (13F) holdings and related news for Jazz Pharmaceuticals PLC are updated in real time on BlackAll Trade.
Jazz Pharmaceuticals PLC trades at $240.74 (-1.27%). Real-time quotes and charts are available on BlackAll Trade.
Jazz Pharmaceuticals PLC has a market cap of about $14.34B. Its P/E ratio is 2077.91.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive da